Shilpa Medicare Limited (SHILPAMED) — Announcement

· NSE 🔴 High Importance Neutral
📢 Key Event
Shilpa Biologicals upgraded to IND A+ rating with Stable outlook
🔄 What Changed
Upgraded from previous rating (not specified in filing)
💡 Investor Takeaway
The upgrade indicates improved creditworthiness for the subsidiary, potentially lowering borrowing costs and boosting investor confidence in the group's financial stability.

Shilpa Medicare announced that its material subsidiary Shilpa Biologicals received an upgraded credit rating of IND A+ from India Ratings and Research, with a Stable outlook, reflecting improved financial health and lower default risk for its bank facilities. This rating action signals stronger creditworthiness for the subsidiary, which may enhance investor confidence in the group's overall financial stability and borrowing capacity.

📄 View Original Announcement (PDF)

About Shilpa Medicare Limited (SHILPAMED)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹9,356.63 Cr P/E: 106.1

View full SHILPAMED stock details →

📡 Get AI alerts when SHILPAMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SHILPAMED — Free

📊 More SHILPAMED filings

See all SHILPAMED filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when SHILPAMED files new disclosures

Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHILPAMED — Free

Free account · 2 AI queries/day